TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36972026
Drug: Dostarlimab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dostarlimab (500 mg) plus carboplatin and paclitaxel
Study: 36972049
Drug: Digital Cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Cognitive Behavioral Therapy for Insomnia (DCBT-I)
Study: 36972105
Drug: Web-based therapist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based therapist tutorial on Prolonged Grief Disorder Therapy (PGDT)
Study: 36972694
Drug: Azithromycin (20-mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (20-mg/kg single oral dose)
Study: 36972738
Drug: Gel Stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel Stent
Study: 36972796
Drug: Direct-acting antivirals
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals (DAAs) treatment for hepatitis C virus (HCV), specific dosage and duration not mentioned.
Study: 36972800
Drug: 26 g
Normalized name: Sunmark Lancet Thin 26 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26 g of freeze-dried wild blueberry (WBB) powder (302 mg anthocyanins)
Study: 36972800
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo (0 mg anthocyanins)
Study: 36973578
Drug: Attribution of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attribution of GWI to behavior (e.g., diet and exercise)
Study: 36973688
Drug: verum Electroacupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: verum Electroacupuncture (vEA) - ten weekly treatment visits at 13 therapeutic acupuncture points
Study: 36973688
Drug: sham Electroacupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham Electroacupuncture (sEA) - weekly treatment visits at 7 non-disease-related acupuncture points
Study: 36973954
Drug: rilonacept 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilonacept 320 mg followed by weekly doses of 160 mg for 6 weeks
Study: 36974462
Drug: Toll-like receptor
Normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toll-like receptor 4 (TLR4) antagonists
Study: 36974462
Drug: Antibiotic resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic resistance genes
Study: 36974574
Drug: Carbon ion
Normalized name: CARBON ION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon ion radiotherapy in combination with immune checkpoint inhibitors (pembrolizumab)
Study: 36974638
Drug: Linagliptin and
Normalized name: linagliptin and empagliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin and allopurinol in combination (Group 4)
Study: 36974653
Drug: Supervised multi-nut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised multi-nut oral food challenge (OFC) using multi-nut butter
Study: 36974714
Drug: Preoperative renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative renal insufficiency (RI) group with current dialysis, eGFR ≤ 30 ml/min/1.73 m² or concomitant anemia
Study: 36974988
Drug: AS01-adjuvanted vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS01-adjuvanted vaccine containing four surface proteins from non-typable
Study: 36975207
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of mRNA COVID-19 vaccine
Study: 36975207
Drug: Fourth dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourth dose of mRNA COVID-19 vaccine
Study: 36975207
Drug: Booster doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster doses (third and fourth doses)
Study: 36975790
Drug: Nifurtimox 60-day
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifurtimox 60-day regimen (10 to 20 mg/kg/day for patients aged <12 years and body weight <40 kg; 8 to 10 mg/kg/day for those aged ≥12 years and body weight ≥40 kg)
Study: 36975790
Drug: Nifurtimox 30-day
Normalized name: nifurtimox 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifurtimox 30-day regimen (10 to 20 mg/kg/day for patients aged <12 years and body weight <40 kg; 8 to 10 mg/kg/day for those aged ≥12 years and body weight ≥40 kg)
Study: 36976619
Drug: SteWARdS Antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: SteWARdS Antibiotic Defence app
Study: 36976624
Drug: TelePhys group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TelePhys group (monthly telemedicine consultation focusing on physical activity coaching)
Study: 36976624
Drug: TeleDiet group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TeleDiet group (monthly telemedicine consultation involving diet coaching)
Study: 36976630
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing (MI) intervention administered by trained nurses, details on dosage and duration not specified.
Study: 36976630
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing (MI) intervention with caregiver participation, details on dosage and duration not specified.
Study: 36976630
Drug: Motivational Interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Interviewing (MI) intervention administered only to individual patients, details on dosage and duration not specified.
Study: 36976630
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving standard care without MI, details on dosage and duration not specified.
Study: 36977289
Drug: Ficlatuzumab Monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ficlatuzumab Monotherapy
Study: 36977292
Drug: Breast-conserving therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-conserving therapy (BCT) including lumpectomies with negative margins followed by whole breast radiation with boost to all lumpectomy beds.
Study: 36977973
Drug: Amcenestrant 400
Normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amcenestrant 400 mg QD
Study: 36977973
Drug: Amcenestrant 300
Normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amcenestrant 300 mg BID
Study: 36978099
Drug: Analgesic therapy
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic therapy for moderate/severe pain
Study: 36978099
Drug: Time-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-based therapy
Study: 36980529
Drug: Clinical risk
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical risk factors used for treatment stratification in the EpSSG RMS 2005 protocol
Study: 36987861
Drug: BBIBP-CorV inactivated
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBIBP-CorV inactivated SARS-CoV-2 vaccine
Study: 36988304
Drug: Individual Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Cognitive Processing Therapy for PTSD
Study: 36988304
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Processing Therapy for PTSD
Study: 36988483
Drug: Optimization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) intervention, details not available
Study: 36988594
Drug: Vedolizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab (300 mg intravenously on day 1 and at weeks 2, 6, 14, 22, and 30)
Study: 36988594
Drug: Vedolizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab (300 mg intravenously)
Study: 36988715
Drug: Tumor response
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor response after neoadjuvant therapy
Study: 36988936
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (cholecalciferol, 100 000 IU loading dose, followed by 20 000 IU/week)
Study: 36989357
Drug: CAdVEC (ultralow
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAdVEC (ultralow dose, single intratumoral injection)
Study: 36989884
Drug: AK109 (anti-VEGFR2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK109 (anti-VEGFR2 monoclonal antibody)
Study: 36990274
Drug: Standard acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard acupuncture (SA; up to 15 treatment sessions across 12 weeks)
Study: 36990475
Drug: VR-assisted cognitive
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR-assisted cognitive behavioural therapy (VR-CBT)
Study: 36990493
Drug: Dynamic risk
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic risk prediction models incorporating adverse events and medications
Study: 36990493
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy and statins at discharge
Study: 36990493
Drug: Age, prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, prior renal dysfunction, history of HF, AMI classification, heart rate, Killip class, haemoglobin, LVEF, in-hospital PCI, HF during hospitalisation, HF worsening within 30 days after discharge, antiplatelet therapy, β blocker and statin use within 30 days after discharge
Study: 36990609
Drug: Toripalimab combined
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab combined with definitive chemoradiotherapy (50·4 Gy in 28 fractions, five cycles of weekly intravenous paclitaxel [50 mg/m²])
Study: 36990622
Drug: Eprenetapopt (4·5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprenetapopt (4·5 g/day on days 1-4) and venetoclax (400 mg/day on days 1-28) with azacitidine (75 mg/m2)
Study: 36990930
Drug: Muscadine grape
Normalized name: Muscadine Grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscadine grape extract supplement (MGES) - four tablets twice daily for 12 weeks
Study: 36990930
Drug: Muscadine grape
Normalized name: Muscadine Grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscadine grape extract supplement (MGES)
Study: 36991169
Drug: OCS-05 (0.05-3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCS-05 (0.05-3.2 mg/kg)
Study: 36991390
Drug: NEO-201 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEO-201 (1 mg/kg, 1.5 mg/kg, 2 mg/kg) administered intravenously every two weeks in a 28-day cycle until DLT, disease progression, or patient withdrawal.
Study: 36991390
Drug: NEO-201 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEO-201 treatment
Study: 36991396
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of raisins daily for 6 months
Study: 36991450
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg oral dextromethorphan hydrobromide preoperatively, 30 mg at 8 h and 16 h postoperatively
Study: 36992863
Drug: 3 years
Normalized name: NanoVM 1-3 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 years of anastrozole (1 mg orally once a day)
Study: 36992863
Drug: 6 years
Normalized name: SymPak PDX, ages 6 years and older oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 years of anastrozole (1 mg orally once a day)
Study: 36992865
Drug: Combining same
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combining same prescriptions
Study: 36992865
Drug: Pill dispenser
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill dispenser
Study: 36992865
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not combining same prescriptions)
Study: 36993363
Drug: Exenatide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (5 µg, sc)
Study: 36993363
Drug: Saline (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.2 mL, sc)
Study: 37391729
Drug: Perioperative ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative ketamine infusion (intraoperative and postoperative for up to 48 hours)
Study: 37391729
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (intraoperative and postoperative for up to 48 hours)
Study: 36993617
Drug: Perioperative ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative ketamine infusion
Study: 36994730
Drug: CSL112 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSL112 infusion
Study: 36995872
Drug: Somapacitan (0.04,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somapacitan (0.04, 0.08, 0.16 mg/kg/week) for 1 year, followed by 0.16 mg/kg/week for 3 years
Study: 36995872
Drug: Somapacitan (0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somapacitan (0.16 mg/kg/week) after switching from daily GH
Study: 36995872
Drug: Daily GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily GH (0.034 mg/kg/day) for 3 years, then somapacitan (0.16 mg/kg/week) for 1 year
Study: 36996150
Drug: Acebilustat 100
Normalized name: Acebilustat
DrugBank: Acebilustat (DB15385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebilustat 100 mg/d for 28 days
Study: 36996185
Drug: Euvax B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euvax B hepatitis B vaccine (Control)
Study: 36996322
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg daily and selpercatinib 80 mg twice daily
Study: 36996373
Drug: Sugemalimab 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugemalimab 1,200 mg intravenously once every 3 weeks for up to 24 months
Study: 36996503
Drug: Topical oxymetazoline
Normalized name: oxymetazoline Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oxymetazoline 0.1%
Study: 36997069
Drug: Brodalumab (interleukin-17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab (interleukin-17 pathway inhibitor)
Study: 36997255
Drug: Online community-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online community-based exercise intervention (CBE) involving thrice weekly exercise (aerobic, resistance, balance, flexibility), biweekly personal training sessions, YMCA membership, wireless physical activity monitor, monthly educational sessions.
Study: 36997386
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of BNT162b2 mRNA COVID-19 vaccine
Study: 36997569
Drug: SB-121 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-121 (oral probiotic formulation) administered once daily for 28 days
Study: 36997569
Drug: SB-121 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-121 (oral probiotic formulation)
Study: 36997799
Drug: Intrathecal nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal nivolumab (50 mg) and intravenous nivolumab (240 mg) every 2 weeks
Study: 36997799
Drug: Intrathecal nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal nivolumab (5, 10, 20, and 50 mg)
Study: 36998024
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual optimised (TAU-O)
Study: 36998617
Drug: High oral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oral loading dose of cholecalciferol (vitamin D)
Study: 36999039
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (IM to IP injections): 10 patients received three vaccines IM biweekly, followed by three vaccines IP biweekly.
Study: 36999039
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (IP to IM injections): 10 patients received IP vaccines first, followed by IM under a similar vaccination schedule.
Study: 36999039
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received the Bcl-XL-peptide-CAF vaccine.
Study: 36999409
Drug: Short dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short dual antiplatelet therapy (DAPT) for one month
Study: 36999528
Drug: High-dose n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose n-3 PUFA (1840 mg eicosapentaenoic acid and 1520 mg docosahexaenoic acid)
Study: 36999533
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa (1200 mg intravenously Q2W)
Study: 36999819
Drug: O2matic oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: O2matic oxygen treatment for 24 hours
Study: 36999819
Drug: Conventional oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oxygen treatment for 24 hours
Study: 36999981
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg once daily
Study: 37000164
Drug: Eganelisib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eganelisib monotherapy (10-60 mg)
Study: 37000164
Drug: Eganelisib in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eganelisib in combination with nivolumab (20-40 mg)
Study: 37000214
Drug: Garadacimab (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garadacimab (700 mg) plus standard of care (SOC)
Study: 37000245
Drug: Personalized risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized risk factor treatment programme in a specialized, protocolized, nurse-led outpatient clinic
Study: 37000245
Drug: Personalized risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized risk factor treatment programme
Study: 37000264
Drug: Pazopanib with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib with Topotecan (400 mg daily)
Study: 37000310
Drug: SpilleFri (therapist-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: SpilleFri (therapist-guided internet-based treatment program)
Study: 37000452
Drug: SOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC plus disulfiram (400 mg daily) and copper (2.5 mg daily)
Study: 37000452
Drug: SOC alkylating
Normalized name: petroleum alkylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC alkylating chemotherapy alone
Study: 37001446
Drug: DKN-01 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DKN-01 monotherapy
Study: 37001446
Drug: DKN-01 in
Normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DKN-01 in combination with paclitaxel
Study: 37001534
Drug: Defibrotide prophylaxis
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide prophylaxis (25 mg/kg per day, four equal doses of 6.25 mg/kg) plus best supportive care
Study: 37001590
Drug: Intratrial mean
Normalized name: ALCOHOL 80 mL in 100 mL INTRACRANIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratrial mean 25(OH)D ≥ 40 ng/mL
Study: 37001859
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (placebo plus chemotherapy)
Study: 37001917
Drug: dCBI +
Approvals — FDA: no, EMA: no, PMDA: no
Description: dCBI + treatment as usual (TAU) for 12 weeks, n=450
Study: 37002654
Drug: Vupanorsen (PF-07285557),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vupanorsen (PF-07285557), dosage and duration not specified
Study: 37003278
Drug: Fitusiran prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitusiran prophylaxis (80 mg subcutaneous once per month)
Study: 37003287
Drug: Fitusiran prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitusiran prophylaxis (80 mg subcutaneous once a month)
Study: 37003287
Drug: Bypassing agents
Normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bypassing agents on-demand
Study: 37003355
Drug: Albuterol-budesonide 180/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol-budesonide 180/160 μg
Study: 37003355
Drug: Albuterol-budesonide 180/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol-budesonide 180/80 μg
Study: 37003355
Drug: Albuterol 180
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 180 μg
Study: 37003355
Drug: Budesonide 160
Normalized name: BUDESONIDE 160/FORMOTER 4.5MCG 60D INH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 160 μg
Study: 37004342
Drug: Myofascial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial treatment (n = 18)
Study: 37004599
Drug: Furmonertinib (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furmonertinib (240 mg once-daily)
Study: 37004599
Drug: Furmonertinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furmonertinib (80 mg once-daily)
Study: 37004599
Drug: Furmonertinib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furmonertinib (160 mg once-daily)
Study: 37004656
Drug: CT-P13 SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P13 SC monotherapy (120 or 240 mg every 2 weeks)
Study: 37004656
Drug: CT-P13 SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P13 SC combotherapy (with immunosuppressants)
Study: 37004656
Drug: CT-P13 SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P13 SC monotherapy
Study: 37004656
Drug: CT-P13 SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P13 SC monotherapy (in ADA-positive patients)
Study: 37004712
Drug: lerapolturev (5 × 10)
Normalized name: Lerapolturev
DrugBank: Lerapolturev (DB17217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lerapolturev (5 × 10) administered as a single dose intracerebrally by convection enhanced delivery
Study: 37004712
Drug: low-dose bevacizumab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose bevacizumab
Study: 37004887
Drug: Methotrexate (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (combination therapy)
Study: 37005580
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (0.3 mg/kg bolus over 10 min, followed by 0.3 mg/kg/h infusion)
Study: 37005580
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (0.5 mcg/kg bolus over 10 min, followed by 0.5 mg/kg/h infusion)